<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02852551</url>
  </required_header>
  <id_info>
    <org_study_id>PAT‑1251‑CL‑001</org_study_id>
    <nct_id>NCT02852551</nct_id>
  </id_info>
  <brief_title>Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of PAT‑1251 in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Randomised, Placebo‑Controlled, Ascending Single and Multiple Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of PAT‑1251 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmAkea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmAkea, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single‑center, randomized, placebo‑controlled study consisting of both a single ascending
      dose (SAD) and a multiple ascending dose (MAD) portion to evaluate the safety, tolerability,
      pharmacokinetics and effect of food using PAT‑1251 orally administered to healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>one to seven days</time_frame>
    <description>Determination of adverse events will include assessment of vital signs, ECG, clinical laboratory and physical examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>one to seven days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC)</measure>
    <time_frame>one to seven days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>one to seven days</time_frame>
    <description>Comparative pharmacokinetics of single dose administered in a fasted state and following a meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t½)</measure>
    <time_frame>one to seven days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PAT-1251 Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral solution of PAT-1251, 150 - 4000 mg administered once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Single Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo solution administered once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAT-1251 Multiple Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet(s) of PAT-1251 up to 2000 mg administered daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Multiple Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matching placebo tablets administered daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAT-1251</intervention_name>
    <arm_group_label>PAT-1251 Single Dose</arm_group_label>
    <arm_group_label>PAT-1251 Multiple Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Single Dose</arm_group_label>
    <arm_group_label>Placebo Multiple Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive

          -  body weight of 50 to 100 kg, inclusive

          -  subjects must be in good health

        Exclusion Criteria:

          -  male subjects who do not agree, or whose partners of childbearing potential do not
             agree, to use appropriate contraception

          -  female subjects of childbearing potential who do not agree to use 2 acceptable methods
             of contraception

          -  history of, any clinically significant major disorder

          -  clinically significant allergic condition

          -  significant history of alcoholism or drug/chemical abuse

          -  use of any tobacco or nicotine‑containing products

          -  clinically significant abnormality in heart rate, blood pressure, temperature,
             respiration rate, electrocardiogram or clinical laboratory findings

          -  positive urine drugs of abuse screen or alcohol breath test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Holme, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>PharmAkea, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Ltd.</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.pharmakea.com</url>
    <description>Sponsor Website</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>September 14, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

